Industry Forum

SYN-TECH CHEM.& PHARM.CO.,LTD

Andrew Wang General Manager

12 Nov. 2020

Stock Code：1777

In these presentations and discussions, there are certain forward looking

statements regarding the results of operation, financial condition and

current expectation about future events. As forward-looking statements

relate to events and depend on circumstances in the future, they involve

risk and uncertainty.

We do not undertake any obligation to publicly revise or update any

forward looking statements for availability of new information, future

events or otherwise. Real result probably differ substantially from those

expected in these forward-looking statements.

2

Brief overall

Main Products

DMF Registration Status

Official Audit Records

3

Performance for operation

Future strategies and forward-looking

Company Brief Introduction

⚫1982, Nov. 9 established

NT $300,595,500 J. M. Hsiao, Chairman 180 employees APIs

National Award in

Medicine Quality

National Award of Out

Research and Developm

Award in Pharmaceutical Te

National Innovation Award

Industrial Sustainable Excellence Aw

Small and medium enterprise Innovation Award

⚫Awards Record ⚫All-round development

Manpower cultivation Business fields Infrastructure Cooperate with

academic units Develop new drugs

with other enterprises

ISO9001 ISO14001 ISO45001 CSR

⚫ISO

5

Muscle Relaxants

Digestive System Drugs

Topical Anesthetic Agents

Respiratory System Drugs

Non- Steroidal Anti- Inflammatory

Antipyretics and Analgesic

Cardiovascular Agents

Intermediates

6

Others

COUNTRY DMF/MF（APIS)

U.S.A 16

Japan 20

Canada 2

Korea 5

Others 25

40 products have passed the TFDA PIC/S GMP inspection.

7

Name of theRegulatory Authority

1st Audit year Number /Audit

U.S.A FDA 1995 6

Taiwan FDA 2002 16

Korea FDA 2007 2

Hungary FDA 2008 1

Japan PMDA 2014 3

Mexico FDA 2015 1

EDQM 2016 1

8

Business and Financial Statements

Unit: NT in million

684

767

695

785

946

761

0

100

200

300

400

500

600

700

800

900

1000

2015 2016 2017 2018 2019 Jan.-Sept., 2020

10

11

Muscle

Relaxants

Topical

Anesthetic

Agents

Respiratory

System Drugs

Digestive

System Drugs

Cardiovascula

r Agents

Non-

Steroidal

Anti-

Inflammatory

Antipyretics

and Analgesic

Intermediates Others

Jan.-Sept., 2020 32% 13% 7% 18% 2% 2% 0% 26%

Jan.-Sept., 2019 37% 13% 6% 13% 4% 2% 2% 23%

24,287

9,979

5,765

13,473

1,6931,285

98

19,500

24,937

8,648

4,398

9,064

2,703

1,238 1,679

15,294

0%

5%

10%

15%

20%

25%

30%

35%

40%Unit: NT in ten thousand

Data collected form Jan.-Sept., 2020

12

13

Unit: NT in million

Item Jan.-Sept., 2020 Jan.-Sept., 2019 Differences

Operating revenue 761 680 81

Gross profit 288 220 68

Gross profit ratio 38% 32% 6%

Operating profit 205 142 63

Profit before tax 189 163 26

Profit after tax 152 128 24

EPS (in dollar) 5.05 4.27 0.78

14

Unit: NT in dollar

5.20 5.27

1.99

5.12 5.31

5.05

3.5 3.5

1.75

3.3 3.5

0.00

1.00

2.00

3.00

4.00

5.00

6.00

2015 2016 2017 2018 2019 Jan.-Sept., 2020

EPS Cash divident

▪ a. Revenue• The sell in API for attention deficit/hyperactivity disorder

continuously increased after it was brought to the market.

• The APIs for digestive system, topical anesthetic andantibacterial are stable growing this year.

• The sell of APIs with small quantity but high unit priceincreased this year.

▪ b. Profit• We extended our focus on the market of Europe, America

and Japan, and their business was not affected afterreasonably adjusted the price for several products.

• The sell of several products with better gross profit marginincreased.

• By improving manufacturing process, several of our productsobtained better profit.

15

Strategy in the Future Development & forward-looking

⚫ Continue to develop new product and expand theirmarket share.

⚫ Continue to improve the manufacture process forexisting products to enhance the competitiveness andprofitability :

• Shorten the manufacture process and improve the overallyield.

• Continue to improve the synthetic approach; so that enableto prevent the unexpected incidences during the manufacture.

17

⚫ Carefully select and evaluate suitable new niche APIsfor company’s future development：• Utilize the advantages of technology and equipment in our

company.

• Choice the products with high-tech threshold and high added-on value.

⚫ Expanding New Business Area：• APIs’ key intermediates.

• Continue to development our business in China market.

• Formulated APIs.

• Macromolecular APIs.

• Cooperate with other companies to develop new medicines.

18

SYN-TECH CHEM.& PHARM.CO.,LTD

生泰合成工業股份有限公司

Thanks for your attention.